GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Standard BioTools Inc (NAS:LAB) » Definitions » Cyclically Adjusted PS Ratio

LAB (Standard BioTools) Cyclically Adjusted PS Ratio : 0.41 (As of May. 28, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Standard BioTools Cyclically Adjusted PS Ratio?

As of today (2025-05-28), Standard BioTools's current share price is $1.09. Standard BioTools's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $2.66. Standard BioTools's Cyclically Adjusted PS Ratio for today is 0.41.

The historical rank and industry rank for Standard BioTools's Cyclically Adjusted PS Ratio or its related term are showing as below:

LAB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.28   Med: 0.85   Max: 2.73
Current: 0.4

During the past years, Standard BioTools's highest Cyclically Adjusted PS Ratio was 2.73. The lowest was 0.28. And the median was 0.85.

LAB's Cyclically Adjusted PS Ratio is ranked better than
88.33% of 480 companies
in the Medical Devices & Instruments industry
Industry Median: 2.215 vs LAB: 0.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Standard BioTools's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.108. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.66 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Standard BioTools Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Standard BioTools's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools Cyclically Adjusted PS Ratio Chart

Standard BioTools Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.90 1.21 0.36 0.70 0.64

Standard BioTools Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.59 0.67 0.64 0.41

Competitive Comparison of Standard BioTools's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Standard BioTools's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Cyclically Adjusted PS Ratio falls into.


;
;

Standard BioTools Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Standard BioTools's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.09/2.66
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Standard BioTools's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.108/134.9266*134.9266
=0.108

Current CPI (Mar. 2025) = 134.9266.

Standard BioTools Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.994 100.684 1.332
201509 0.996 100.392 1.339
201512 1.066 99.792 1.441
201603 1.005 100.470 1.350
201606 0.973 101.688 1.291
201609 0.763 101.861 1.011
201612 0.860 101.863 1.139
201703 0.873 102.862 1.145
201706 0.815 103.349 1.064
201709 0.717 104.136 0.929
201712 0.716 104.011 0.929
201803 0.650 105.290 0.833
201806 0.678 106.317 0.860
201809 0.738 106.507 0.935
201812 0.779 105.998 0.992
201903 0.516 107.251 0.649
201906 0.408 108.070 0.509
201909 0.381 108.329 0.475
201912 0.465 108.420 0.579
202003 0.392 108.902 0.486
202006 0.367 108.767 0.455
202009 0.550 109.815 0.676
202012 0.600 109.897 0.737
202103 0.439 111.754 0.530
202106 0.411 114.631 0.484
202109 0.374 115.734 0.436
202112 0.499 117.630 0.572
202203 0.344 121.301 0.383
202206 0.241 125.017 0.260
202209 0.325 125.227 0.350
202212 0.340 125.222 0.366
202303 0.318 127.348 0.337
202306 0.352 128.729 0.369
202309 0.320 129.860 0.332
202312 0.354 129.419 0.369
202403 0.155 131.776 0.159
202406 0.100 132.554 0.102
202409 0.121 133.029 0.123
202412 0.125 133.157 0.127
202503 0.108 134.927 0.108

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Standard BioTools  (NAS:LAB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Standard BioTools Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Standard BioTools's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Standard BioTools Business Description

Traded in Other Exchanges
Address
2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Executives
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black officer: SVP & Chief Financial Officer 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Fo1-msv, Lp director C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p. director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis officer: SVP Chief Commercial Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim officer: Chief Operating Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm director, officer: President & CEO 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110